丹参酮ⅡA磺酸钠注射液治疗急性心肌梗死患者的临床效果分析  

Analysis on the Clinical Effect of TanshinoneⅡA Sodium Sulfonate Injection in the Treatment of Patients with Acute Myocardial Infarction

作　　者：郑培鑫[1] 黄华[1] 郑林立 ZHENG Peixin;HUANG Hua;ZHENG Linli(Department of Cardiology,Shantou Second People's Hospital,Shantou 515011,China)

机构地区：[1]广东省汕头市第二人民医院心内科,广东汕头515011

出　　处：《临床医学工程》2021年第11期1515-1516,共2页Clinical Medicine & Engineering

摘　　要：目的探讨丹参酮ⅡA磺酸钠注射液治疗急性心肌梗死(AMI)患者的临床效果。方法选择我院2016年5月至2020年9月收治的40例AMI患者,随机分为常规组(n=20,常规治疗)与丹参酮组(n=20,常规治疗+参酮ⅡA磺酸钠注射液)。比较两组的血清NT-proBNP、CK-MB、CRP水平以及LVEF、LVDD、SV;统计两组不良反应发生情况。结果丹参酮组的CRP、NT-proBNP、CK-MB水平低于常规组,SV、LVEF、LVDD高于常规组,不良反应发生率低于常规组(P<0.05)。结论丹参酮ⅡA磺酸钠注射液治疗AMI患者的疗效显著,改善其心功能,安全性较高,值得临床推广应用。Objective To explore the clinical effect of tanshinoneⅡA sodium sulfonate injection in the treatment of patients with acute myocardial infarction(AMI).Methods 40 AMI patients admitted to our hospital from May 2016 to September 2020 were selected and randomly divided into routine group(n=20,routine treatment)and tanshinone group(n=20,routine treatment+tanshinoneⅡA sodium sulfonate injection).The serum NT-proBNP,CK-MB and CRP levels,and the LVEF,LVDD and SV were compared between the two groups.The adverse reactions of the two groups were recorded.Results The CRP,NT-proBNP and CK-MB levels of the tanshinone group were lower than those of the routine group,the SV,LVEF and LVDD were higher than those of the routine group,and the incidence of adverse reactions was lower than that of the routine group(P<0.05).Conclusions TanshinoneⅡA sodium sulfonate injection in the treatment of AMI patients has significant efficacy,and can effectively improve the cardiac function,with higher safety,which is worthy of clinical promotion and application.

关 键 词：丹参酮ⅡA磺酸钠注射液 急性心肌梗死 心功能 临床效果 

分 类 号：R542.22[医药卫生—心血管疾病]